Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma

Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma

Treatment for endometrial cancer is rapidly evolving with the increased use and integration of somatic tumor RNA sequencing in clinical practice. There is a paucity of data regarding PARP inhibition in endometrial cancer given that mutations in homologous recombination genes are rare, and currently...

Full description

Bibliographic Details
Main Authors: Rosemary Noel Senguttuvan, Christina Wei, Mustafa Raoof, Thanh H. Dellinger, Edward Wenge Wang
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Journal of Clinical Medicine
Subjects:
endometrial cancer
PARP inhibition
pathologic complete response
Olaparib
BRIP1 mutation
ATM mutation
Online Access:https://www.mdpi.com/2077-0383/12/11/3839

Internet

https://www.mdpi.com/2077-0383/12/11/3839

Similar Items